caa a22 4500 475818288 CHVBK 20180406123815.0 cr unu---uuuuu 170329e20000601xx s 000 0 eng 10.1007/s002280000129 doi (NATIONALLICENCE)springer-10.1007/s002280000129 Psychomotor effects of zaleplon and thioridazine coadministration [Elektronische Daten] [J. Hetta, J.-E. Broman, M. Darwish, S. M. Troy] Objective: To assess the potential pharmacokinetic and pharmacodynamic interaction of zaleplon and thioridazine administered concomitantly in healthy volunteers. Methods: A three-period, double-blind, randomized crossover study of the psychomotor effects of single oral doses of zaleplon 20 mg alone, thioridazine 50 mg alone, or the two drugs administered concomitantly was performed in 12 healthy subjects. Pharmacodynamic testing was performed before, and at 1, 2, 4, and 8 h after drug administration. Critical flicker fusion (CFF), tapping rate (TR), reaction time (RT) with dominant and nondominant hands, and digit symbol substitution test (DSST) were used to assess psychomotor performance. Results: Pharmacokinetic results showed that coadministration of zaleplon and thioridazine did not alter the pharmacokinetic profile of either drug. In both CFF and TR tests, values for change from baseline with combined treatment were not significantly different from those with thioridazine at any time point, indicating no pharmacodynamic interaction. RT test values with coadministered treatment were significantly different from those with thioridazine alone at 1 h after administration, indicating additivity. Supra-additivity was observed in DSST results at 1, 2, and 4 h. There was no interaction at 8 h. Conclusion: The results of single-dose administration showed an additive pharmacodynamic interaction between zaleplon and thioridazine at 1 h in one of four tests and supra-additivity for 4 h in another test. This interaction is relatively short in duration due to the short half-life of zaleplon. Springer-Verlag Berlin Heidelberg, 2000 Key words Zaleplon nationallicence Thioridazine nationallicence Drug interactions nationallicence Hetta J. Department of Psychiatry, University Hospital, Uppsala, Sweden, SE aut Broman J.-E Department of Psychiatry, University Hospital, Uppsala, Sweden, SE aut Darwish M. Clinical Pharmacokinetics, Wyeth-Ayerst Research, 145 King of Prussia Road, Radnor, PA 19087, USA e-mail: darwism@war.wyeth.com Tel.: +1-610-3412390; Fax: +1-610-9894574, RU aut Troy S. M. Clinical Pharmacokinetics, Wyeth-Ayerst Research, 145 King of Prussia Road, Radnor, PA 19087, USA e-mail: darwism@war.wyeth.com Tel.: +1-610-3412390; Fax: +1-610-9894574, RU aut https://doi.org/10.1007/s002280000129 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280000129 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hetta J. Department of Psychiatry, University Hospital, Uppsala, Sweden, SE aut NATIONALLICENCE 700 1- Broman J.-E Department of Psychiatry, University Hospital, Uppsala, Sweden, SE aut NATIONALLICENCE 700 1- Darwish M. Clinical Pharmacokinetics, Wyeth-Ayerst Research, 145 King of Prussia Road, Radnor, PA 19087, USA e-mail: darwism@war.wyeth.com Tel.: +1-610-3412390; Fax: +1-610-9894574, RU aut NATIONALLICENCE 700 1- Troy S. M. Clinical Pharmacokinetics, Wyeth-Ayerst Research, 145 King of Prussia Road, Radnor, PA 19087, USA e-mail: darwism@war.wyeth.com Tel.: +1-610-3412390; Fax: +1-610-9894574, RU aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer